Scientists identify potent new anti-obesity, anti-diabetes target

October 12, 2016, The Scripps Research Institute

It is no secret that losing weight is difficult. Each year brings a new popular diet, "guaranteed" to succeed, yet the explosion of obesity in the United States continues.

Current anti-obesity medications are only partly effective, due to substantial side effects, the temporary nature of the and the non-responsiveness of a considerable number of patients.

In a recently published series of studies led by TSRI Assistant Professor Anutosh Chakraborty of the Florida campus of The Scripps Research Institute (TSRI), scientists have identified a new therapeutic target—a key protein that promotes in animal models by slowing the breakdown and expenditure of fat and encouraging .

The studies were published in The International Journal of Biochemistry & Cell Biology, Molecular Metabolism and, most recently, The Journal of Clinical Investigation.

"We found that the protein IP6K1 is a viable target in obesity and type 2 diabetes," Chakraborty said. "We also discovered that an inhibitor of the protein known as TNP decelerates what is known as diet-induced obesity and insulin resistance."

In the last few years, enhancing energy expenditure has emerged as an attractive strategy to combat obesity and diabetes, although how this might be accomplished remains something of a mystery simply because the mechanisms by which the body maintains its energy balance is complex.

The new studies point to IP6k1 (inositol hexakisphosphate kinase-1), specifically its inhibition, as a potentially rich target. Chakraborty and his colleagues found that deleting IP6K1 in fat cells enhanced energy expenditure and protected animal models from diet-induced obesity and insulin resistance.

The expenditure of fat energy is preceded by a process called lipolysis that breaks down stored fat or triglycerides (specifically into free fatty acids and glycerol) to be used as energy in cells. The team discovered that deletion of IP6K1 affects interaction with another regulating protein and enhances the breakdown of fats.

To determine the therapeutic possibilities of the IP6K1 pathway, the team looked at the impact of an IP6K inhibitor known as TNP [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl) purine] on diet-induced obesity in animal models. As it turns out, TNP significantly slows the initiation of diet-induced obesity and insulin resistance.

"In addition, the compound facilitates weight loss and improves metabolic parameters when used in animals that are already obese," said Chakraborty.

Explore further: Loss of inflammatory signaling molecule protects mice against diet-induced obesity

More information: Qingzhang Zhu et al, Adipocyte-specific deletion of Ip6k1 reduces diet-induced obesity by enhancing AMPK-mediated thermogenesis, Journal of Clinical Investigation (2016). DOI: 10.1172/JCI85510

Related Stories

Loss of inflammatory signaling molecule protects mice against diet-induced obesity

May 19, 2016
Obesity and subsequent complications are increasing in frequency worldwide. The accumulation of adipose tissue is associated with increased inflammation, and it has been proposed that modification of proinflammatory responses ...

Brain receptor regulates fat burning in cells

January 12, 2016
Scientists at the Gladstone Institutes have discovered an unusual regulator of body weight and the metabolic syndrome: a molecular mechanism more commonly associated with brain cells. Lowering levels of P75 neurotrophin receptor ...

Improving obesity-induced insulin sensitivity

June 1, 2012
In recent years, a growing body of evidence has linked inflammation to the development of insulin resistance. In insulin resistance, the hormone insulin is less effective in promoting glucose uptake from the bloodstream into ...

Fish oil pills reverse the effects of a fatty diet

August 24, 2016
Scientists have found that fish oil supplements can reverse the effects of a high fat diet according to a study published in the Journal of Physiology.

Calorie-restricted weight loss restores ghrelin sensitivity

January 21, 2013
(HealthDay)—In a mouse model, calorie-restricted weight loss reverses the high-fat diet-induced ghrelin resistance that may contribute to rebound weight gain, according to research published online Jan. 10 in Endocrinology.

Researchers discover potential avenue to treating type 2 diabetes at early stages

August 8, 2016
Researchers at the Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a new potential target for drugs to prevent type 2 diabetes. A paper published today in the Journal of Clinical Investigation shows ...

Recommended for you

Study examines disruption of circadian rhythm as risk factor for diseases

December 11, 2018
USC scientists report that a novel time-keeping mechanism within liver cells that helps sustain key organ tasks can contribute to diseases when its natural rhythm is disrupted.

New light-based technology reveals how cells communicate in human disease

December 11, 2018
Scientists at the University of York have developed a new technique that uses light to understand how cells communicate in human disease.

Researchers explore new way of killing malaria in the liver

December 8, 2018
In the ongoing hunt for more effective weapons against malaria, international researchers said Thursday they are exploring a pathway that has until now been little studied—killing parasites in the liver, before the illness ...

Study may offer doctors a more effective way to treat neuroblastoma

December 7, 2018
A very large team of researchers, mostly from multiple institutions across Germany, has found what might be a better way to treat patients with neuroblastoma, a type of cancer. In their paper published in the journal Science, ...

Progress made in transplanting pig hearts into baboons

December 6, 2018
A large team of researchers from several institutions in Germany, Sweden, Switzerland and the U.S. has transplanted pig hearts into baboons and kept them alive for an extended period of time. In their paper published in the ...

'Chemo brain' caused by malfunction in three types of brain cells, study finds

December 6, 2018
More than half of cancer survivors suffer from cognitive impairment from chemotherapy that lingers for months or years after the cancer is gone. In a new study explaining the cellular mechanisms behind this condition, scientists ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.